Suppr超能文献

仿制药入门:监管方面与科学概念

A generic drug primer: regulatory aspects and scientific concepts.

作者信息

Henderson J D, White G L

机构信息

Department of Physician Assistant Studies, College of Allied Health Professions, University of South Alabama, Mobile 36604, USA.

出版信息

Mil Med. 1998 Apr;163(4):193-7.

PMID:9575760
Abstract

The regulatory aspects of generic drug substitution and the scientific concepts that serve as the basis for generic drug approval are discussed, with emphasis on the source of therapeutic equivalence information compiled by the Food and Drug Administration in Approved Drug Products with Therapeutic Equivalence Evaluations. The Food and Drug Administration's determination of bioequivalence for immediate-release and extended-release dosage forms is summarized, with a discussion of the underlying assumptions and current issues regarding bioequivalence testing. Medical practitioners must comply with the regulations stated in each state's Pharmacy Practice Act when allowing generic substitution and should ensure that the substituted product is therapeutically equivalent to the prescribed product.

摘要

本文讨论了仿制药替代的监管方面以及作为仿制药批准基础的科学概念,重点是美国食品药品监督管理局(FDA)在《有治疗等效性评估的已批准药品》中汇编的治疗等效性信息的来源。总结了FDA对速释和缓释剂型生物等效性的判定,并讨论了生物等效性测试的基本假设和当前问题。医生在允许仿制药替代时必须遵守每个州《药房实践法》规定的法规,并应确保替代产品在治疗上等同于处方产品。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验